Ryan Hoshi

Placeholder Person Graphic
AbbVie
Director, Regulatory Policy & Intelligence
Ryan A. Hoshi, PhD, MBA, is Director of Regulatory Policy and Intelligence at AbbVie and serves as the global policy lead for digital health, medical devices, combination products, personalized medicine, biotherapeutics, clinical pharmacology, and advanced medical therapeutics. Prior to AbbVie, Ryan served as an international policy analyst at the Center for Devices and Radiological Health in the US FDA and promoted international regulatory harmonization activities through the Asia Pacific Economic Cooperation Regulatory Harmonization Steering Committee, Medical Device Single Audit Program, and International Medical Device Regulators Forum. Ryan also worked on drug policy at the Center for Drug Evaluation and Research and as a Lead Re-viewer in CDRH on interventional cardiology devices and drug-eluting stents. Ryan earned his bachelor’s degree in bioengineering from the University of California, Berkeley, his doctorate and master’s degrees in biomedical engineering from Northwestern University, and his MBA from Georgetown University, McDonough School of Business. He has been an ISPE member since 2021.

Related Articles

Challenges & Opportunities in Emerging Digital Health Technologies
Features
Challenges & Opportunities in Emerging Digital Health Technologies

Digital health is transforming the health care landscape through new technologies and platforms in patient care management, conducting of clinical trials, patient data collection, and the diagnosis and treatment of disease. Emerging digital health technologies (DHTs) may improve the quality of life for patients with chronic and debilitating diseases and provide novel health care solutions for...

China’s Regulatory Framework for Combination Products: Ongoing Challenges and Potential Opportunities
iSpeak Blog
China’s Regulatory Framework for Combination Products: Ongoing Challenges and Potential Opportunities

As the world’s second largest market for pharmaceuticals and accounting for 20% of global medical device sales with double digit annual growth, the Chinese market is poised to have a significant impact on expanding patient access to innovative therapies and combination products (CPs). 1

  • 1Chinese Medical Device Industry: How to thrive in an increasingly competitive market?